Kapoor Anmol S, Kanji Hussein, Buckingham Jeanette, Devereaux P J, McAlister Finlay A
Division of General Internal Medicine, University of Alberta, 8440 112 Street, Edmonton, AB, Canada T6G 2R7.
BMJ. 2006 Dec 2;333(7579):1149. doi: 10.1136/bmj.39006.531146.BE. Epub 2006 Nov 6.
To determine the strength of evidence underlying recommendations for use of statins during the perioperative period to reduce the risk of cardiovascular events.
Systematic review of studies with concurrent control groups.
Four electronic databases, the references of identified studies, international experts on perioperative medicine, and the authors of the primary studies. Review methods Two reviewers independently extracted data from studies that reported acute coronary syndromes or mortality in patients receiving or not receiving statins during the perioperative period.
Random effects summary odds ratios for death or acute coronary syndrome during the perioperative period.
18 studies--two randomised trials (n=177), 15 cohort studies (n=799,632), and one case-control study (n=480)--assessed whether statins provide perioperative cardiovascular protection; 12 studies enrolled patients undergoing non-cardiac vascular surgery, four enrolled patients undergoing coronary bypass surgery, and two enrolled patients undergoing various surgical procedures. In the randomised trials the summary odds ratio for death or acute coronary syndrome during the perioperative period with statin use was 0.26 (95% confidence interval 0.07 to 0.99) and the summary odds ratio in the cohort studies was 0.70 (0.57 to 0.87). Although the pooled cohort data provided a statistically significant result, statins were not randomly allocated, results in retrospective studies were larger (odds ratio 0.65, 0.50 to 0.84) than those in the prospective cohorts (0.91, 0.65 to 1.27), and dose, duration, and safety of statin use was not reported.
The evidence base for routine administration of statins to reduce perioperative cardiovascular risk is inadequate.
确定围手术期使用他汀类药物以降低心血管事件风险的相关推荐所依据的证据强度。
对设有同期对照组的研究进行系统评价。
四个电子数据库、已识别研究的参考文献、围手术期医学国际专家以及原始研究的作者。
两名评价者独立从报告围手术期接受或未接受他汀类药物治疗患者的急性冠状动脉综合征或死亡率的研究中提取数据。
围手术期死亡或急性冠状动脉综合征的随机效应汇总比值比。
18项研究——两项随机试验(n = 177)、15项队列研究(n = 799,632)和一项病例对照研究(n = 480)——评估了他汀类药物是否能提供围手术期心血管保护;12项研究纳入了接受非心脏血管手术的患者,4项纳入了接受冠状动脉搭桥手术的患者,2项纳入了接受各种外科手术的患者。在随机试验中,围手术期使用他汀类药物时死亡或急性冠状动脉综合征的汇总比值比为0.26(95%置信区间0.07至0.99);在队列研究中汇总比值比为0.70(0.57至0.87)。尽管汇总队列数据得出了具有统计学意义的结果,但他汀类药物并非随机分配,回顾性研究的结果(比值比0.65,0.50至0.84)大于前瞻性队列研究的结果(0.91,0.65至1.27),且未报告他汀类药物使用的剂量、持续时间和安全性。
常规使用他汀类药物降低围手术期心血管风险的证据不足。